High-risk Corneal Transplantation: Recent Developments and Future Possibilities.

In contrast, a randomized, controlled trial of oral CsA compared to topical corticosteroid alone showed a nonsignificant trend toward a higher rejection rate in CsA-treated high-risk recipients (30% versus 16%) with similar graft survival (45% versus 42%). 42 Available clinical trial evidence does not support the use of topical CsA either in the prevention of graft rejection in high-risk corneal transplantation. 41 Other s

also in 5,406 other papers